Hemcheck receives follow up order from its UK distributor

SOLNA, Sweden, Nov. 2, 2022 /PRNewswire/ -- Hemcheck Sweden AB has today received a follow-up order from its British distributor CLS. The order is of smaller size but shows that CLS is active in the market and that British customers are in demand of Hemcheck's products.

"It is always exciting with a new order, and we believe strongly in the collaboration with CLS. The UK market is very large, and our products have good potential there. We look forward to a continued good cooperation with CLS and hope for several recurring orders," says Joen Averstad, CEO of Hemcheck.

For further information contact:

Hemcheck Sweden AB (publ) 
Joen Averstad, CEO
Tel: +46 76 108 8191
Email: joen.averstad@hemcheck.com

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Hemcheck's goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.

The following files are available for download: